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Abstract
Background: Breast Cancer 1 gene (BRCA1) is known to be inactivated in breast tumors by promoter methylation. Tumor cells
in patients carrying a germline mutation in BRCA1 are sensitive to cytotoxic drugs that cause DNA double strand breaks.
However, very little is known on whether patients with BRCA1 promoter methylated tumors are similarly sensitive to
cytotoxic drugs. In this study, we address this by making use of extensive follow-up data on patients treated with cyclophos-
phamide, methotrexate, and fluorouracil in Iceland between 1976 and 2007.
Methods: We analyzed BRCA1 promoter methylation by pyrosequencing DNA from tumor samples from 1031 patients with
primary breast cancer. Of those, 965 were sporadic cases, 61 were BRCA2, and five were BRCA1 germline mutation carriers. All
cases were examined with respect to clinicopathological parameters and breast cancer–specific survival in patients treated
with cytotoxic drugs. Information on chemotherapy treatment in noncarriers was available for 26 BRCA1 methylated tumors
and 857 unmethylated tumors.
Results: BRCA1 was promoter methylated in 29 sporadic tumors or in 3.0% of cases (29 of 965), whereas none of the tumors
derived from BRCA germline mutation carriers were promoter methylated. Important to note, patients with BRCA1 promoter
methylation receiving chemotherapeutic drug treatment show highly improved breast cancer–specific survival compared
with unmethylated controls (hazard ratio¼0.10, 95% confidence interval ¼ 0.01 to 0.75, two-sided P¼ .02).
Conclusions: BRCA1 promoter methylation is predictive of improved disease outcome in patients receiving
cyclophosphamide, methotrexate, and fluorouracil drug treatment. Our results support the use of markers indicative of
“BRCAness” in sporadic breast cancers to identify patients that are likely to benefit from the use of DNA-damaging
agents.
Germline mutations in the breast cancer–susceptibility gene,
Breast Cancer 1 gene (BRCA1), significantly increase the risk of
developing breast and ovarian cancer, in addition to other
forms of cancer (1). The BRCA1 protein product is involved in
DNA double strand–break (DSB) repair by homologous recom-
bination, a highly conserved error-free DNA–repair pathway
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that uses an intact sister chromatid in late S or G2 phases of
the cell cycle for the repair (2).
Tumors lacking BRCA1 or BRCA2 are homologous recombina-
tion deficient (HRD) and are characterized by mutational signa-
tures, including indels, rearrangements, and base substitutions
(3,4). Based on these mutational signatures, a model, HRDetect,
has been developed to predict the BRCA1/BRCA2 deficiency or
“BRCAness” of tumors (3).
Loss of the wild-type allele is seen in most tumors
arising in BRCA1 mutation carriers (5). These tumors have
high HRDetect scores compared with those that do not
show loss of heterozygosity at the BRCA1 loci. Tumors with-
out loss of heterozygosity have similar HRDetect scores as
noncarriers.
Germline mutations in BRCA genes and somatic mutations
in homologous recombination genes are associated with in-
creased sensitivity to platinum chemotherapy and Poly ADP
Ribose Polymerase (PARP) inhibitors in breast cancer (6–10) and
ovarian cancer (11–15). These agents induce replication fork
stalling, creating DNA substrates that are dependent on homol-
ogous recombination for replication restart and are essential for
the survival of the cell (16).
BRCA1 is sometimes inactivated in breast tumors by pro-
moter methylation (17,18). BRCA1 methylated tumors are as-
sociated with the basal-like or triple-negative subtype that is
predominant in germline mutation carriers (19,20). Recently
BRCA1 methylated tumors were associated with mutational
signatures characteristic of tumors arising in BRCA1 germline
mutation carriers (4,21).
It is currently unclear, however, whether BRCA1 promoter
methylation translates to clinical benefits from the use of DNA-
damaging agents in patients. We therefore carried out a large
retrospective study aimed at determining whether BRCA1 meth-




The study group consisted of 1031 patients (women) diagnosed
between 1976 and 2007 previously screened for the local BRCA1
c.5074G>A and BRCA2 c.767-771delCAAAT–germline mutations
(22,23). In addition to the two BRCA founder mutations, BRCA2
c.767-771delCAAAT and the much rarer BRCA1 c.5074G>A, the
only other BRCA mutation of some frequency, c.9976A>T, is
not found to be associated with risk of breast or ovarian
cancer but rather risk of small cell lung cancer and squamous
cell carcinoma of the skin (24). Out of the 1031 cases, 965 were
sporadic, 61 were BRCA2 germline mutation carriers, and five
were BRCA1 mutation carriers. DNA samples from these
patients were extracted from FF tissue samples (n¼ 417) and
adjacent normal breast tissues (n¼ 91) using a standard phe-
nolchloroform (þ proteinase K) method. DNA derived from
formalin-fixed and paraffin-embedded tumors (n¼ 615) was
extracted by deparaffinization using Octane followed by two
rounds of ethanol washes and then overnight incubation in di-
gestion buffer (50 mM Tris pH 8.8, 1 mM EDTA and 0.5% Tween,
proteinase K).
This work was carried out according to the permits from the
Icelandic Data Protection Commission (2006050307) and
Bioethics Committee (VSNb2006050001/03–16).
DNA–Methylation Analysis
The EZ-96 DNA Methylation-Gold kit (Zymo Research; D5008)
was used to carry out bisulfite conversion of DNA samples de-
rived from tumor and normal breast tissues. Primer design was
based on the PyroMark Assay Desing 2.0 software (Qiagen). Pre-
PCR reactions, using the Immolase DNA polymerase (Bioline;
Bio-21047), along with pyrosequencing (PyroMark Q24; Qiagen)
were carried as previously described (25). Four CpG sites were
analyzed at genetic positions: chr17: 43125409(GRCh38.p7),
chr17: 43125411(GRCh38.p7), chr17: 43125419(GRCh38.p7), chr17:
43125427(GRCh38.p7).
The primers used for pre-PCR were as follows: Forward
primer 5-GTAGGGGTTTAGTTATTTGAGAAATTTT-3; reverse
biotinylated primer 5-TATCCCTCCCATCCTCTAATTATAC-3.
The sequencing primer for the pyrosequencing reaction was as
follows: 5-AGTTTTAATTTATTTGTAATTTT-3. Tumor samples
were considered to be BRCA1 methylated at median greater
than 10% methylation across the four CpGs (median values).
Clinicopathological Parameters and Treatment
Information on patient age, birth date, and date of diagnosis, tu-
mor grade, staging, and chemotherapy treatment given at time
of diagnosis were obtained from the nationwide Icelandic
Cancer Registry (26,27). Estrogen-receptor (ER) status was based
on tissue-microarray (TMA) analysis (n¼ 664) (20,26) and, where
TMA data were not available, we used data derived from routine
clinical diagnoses based on dextran-coated charcoal assay used
in Iceland in the period 1981 to 1995 (n¼ 98).
Statistical Analysis
The v2 and Fisher exact contingency table tests were carried out
using base functions in R. The Kaplan–Meier method was used
for generating univariable survival curves and the log-rank test
was used for estimating P values. Hazard ratios (HRs) were esti-
mated by applying the Cox proportional hazards model using R
(survival package). Here, BRCA1–methylation status represents
the main variable, whereas year of birth, year of diagnosis, ER
status, nodal status, and tumor size are introduced as adjust-
ment covariates. Patients were followed from the date of diagno-
sis until death or date of last follow-up (December 31, 2016). The
endpoint was breast cancer–specific survival, defined as the
time from diagnosis to death from breast cancer, as registered
on death certificates. Patients who died of causes other than
breast cancer were censored at the date of death. The cox.zph
function in the survival package for R was used to test the pro-
portional hazards assumption for a Cox regression model fit. All
tests were two-sided and a P value of less than .05 was consid-
ered statistically significant.
Results
The Incidence of BRCA1 Methylation in Primary Breast
Tumors and Normal Tissue
We analyzed BRCA1 promoter CpG methylation in 1031 pri-
mary tumors, along with 91 normal breast tissue samples de-
rived from the same cohort. BRCA1 methylation was identified
in 29 tumors, none of which were derived from carries of germ-
line mutations in either BRCA1 (n¼ 5) or BRCA2 (n¼ 61)
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(Figure 1). The frequency of BRCA1 promoter methylation in
non-BRCA mutated breast tumors is approximately 3% (29 out
of 965; 3.0%).
BRCA1 Methylation in Relation to Clinicopathological
Parameters
Information on ER status was available for 762 out of the 1031
tumors in our cohort; 700 out of the 762 tumors were derived
from noncarriers (Table 1, A). We find that 90.5% of tumors with
BRCA1 promoter methylation are negative for ER, or 19 out of 21
(see Table 1, A). Similarly, tumors arising in BRCA1 mutation
carriers were exclusively ER negative (five out of five) as previ-
ously reported (20), and by TMA analysis, we find that the ma-
jority of BRCA1 methylated tumors are of the basal-like subtype
(eight out of 12; 67%) (see Table 1, B).
BRCA1 promoter-methylated tumors are statistically signifi-
cantly less differentiated based on histopathological grading
(X2¼11.1, P¼ .0039) (Table 1, C). However, no association was
found with respect to clinical staging in terms of tumor size or
nodal status (Table 1, D and E).
The Effects of BRCA1 Methylation with Respect to
Responsiveness to Cytotoxic Treatment
To assess the association between BRCA1 methylation and re-
sponse to cytotoxic chemotherapy, we obtained information on
chemotherapy and used time to patient death (breast cancer–
specific survival) as a proxy for treatment response. In our co-
hort, cyclophosphamide, methotrexate, and fluorouracil (CMF)
was the most commonly used cytotoxic treatment given at time
of diagnosis, and nine of 29 patients with BRCA1 methylated
tumors received CMF treatment (Table 2). Information on che-
motherapy treatment in noncarriers was available for 26 BRCA1
methylated tumors and 857 unmethylated tumors. In noncar-
riers, patients with BRCA1 methylated tumors show long-term
survival following cytotoxic treatment (HR¼ 0.10, 95% CI¼ 0.014
to 0.751, P¼ .025) (Figure 2, A; Table 3). In contrast, nontreated
patients with BRCA1 methylation, compared with nontreated
patients without BRCA1 methylated tumors, showed similar
time to breast cancer–specific death (Figure 2, B; Table 3). In
comparing treated vs nontreated survival curves for non-BRCA
mutated cases (Figure 2, A and B), there are notable differences,
but these are likely explained by clinical presentation reflecting
poor prognosis, and as a result, the treated group is biased to-
ward reduced survival. This, however, does not affect our
results, as we find improved survival for patients with BRCA1–
methylated tumors after receiving cytotoxic treatment.
In this cohort, nine patients with BRCA1 methylated tumors
received chemotherapeutic treatment with CMF (Table 2).
However, patients with non-BRCA1 methylated tumors received
CMF or other treatments. By restricting our analysis to CMF–
treated patients only, we find that the relation between BRCA1
methylation and breast cancer–specific survival holds statistical
significance (HR¼ 0.11, 95% CI¼ 0.014 to 0.81, P¼ .03).
Discussion
In this article, we demonstrate that BRCA1 promoter methyla-
tion, analyzed in a large cohort of 1031 primary breast tumors,
predicts improved breast cancer–specific survival outcomes in
patients treated with cytotoxic chemotherapy. No difference is
seen in patients that did not receive a cytotoxic treatment, sug-
gesting that BRCA1 promoter methylation is a predictive factor
for chemosensitivity but not a prognostic factor. Previous stud-
ies have shown that BRCA1 mutation carriers are sensitive to
treatment with platinum and PARP inhibitors. However, little is
known about the effect of BRCA1 methylation with respect to
treatment based on DNA–damaging agents.
The classical CMF combination was the standard treatment
for breast cancer patients until it was replaced by anthracy-
clines and taxanes as adjuvant treatment (28). Although it is
less effective than anthracyclines and taxanes, large retrospec-
tive studies have shown a clear benefit of CMF, especially in tri-
ple-negative breast cancer (29–31). Although both methotrexate
and fluorouracil (5-FU) are antimetabolites that block the syn-
thesis of thymidine required for DNA synthesis, cyclophospha-
mide is an alkylating agent, and its cytotoxic metabolite
phosphoramide mustard leads to inter- and intrastrand cross-
links in DNA causing replication fork stalling (32–34). Because of
the importance of the DNA DSB repair machinery in DNA–repli-
cation restart, phosphoramide mustard treatment is likely to
lead to synergistic lethality in BRCA–deficient cells. This mecha-
nism of action is similar to that currently thought to underlie
the effectiveness of PARP1 inhibitors and platinum drugs in kill-
ing BRCA deficient cells (16). The mechanism of PARP1 inhibi-
tion is however more complex than previously expected. In
addition to generating persistent single-strand breaks leading
to collapse of the DNA–replication fork, PARP1 becomes trapped
on DNA when inhibited, forming a cytotoxic lesion leading to
replication fork stalling (35). Recently PARP inhibitors were also
shown to affect the recruitment of POLQ to DNA DSBs, inhibit-
ing microhomology-mediated end joining or Alt-EJ pathway
(36–38).
Recent data have shown that 40–70% of triple-negative
breast cancer is HR deficient (3,4,39) and therefore likely to re-
spond to agents causing DNA–replication fork stalling (40–43).
Replication fork stalling possibly explains the efficacy of
Figure 1. Box plot of BRCA1–promoter CpG methylation in normal breast tissue
and tumors derived from carriers of germline mutations in BRCA1, BRCA2, and
noncarriers.
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cyclophosphamide in triple-negative tumors (30,31), as these
are likely to be HRD.
HRDetect is a recently introduced method that makes use
of next-generation sequencing for identifying mutational
signatures characteristic of tumors arising in BRCA1 or BRCA2
germline mutation carriers (3). The main idea behind HRDetect
is to enable identification of tumors with defective homologous
recombination repair. Indeed, Davies et al. found that tumors
with BRCA1 methylation were detected as HRD by HRDetect (3).
However, it is unclear whether this finding translates to en-
hanced sensitivity of BRCA1 methylated tumors to treatment
with DNA–damaging agents. Our results suggest that, indeed,
this does seem to be the case. It is important to note that
HRDetect genomic signatures might still persist after restored
homologous recombination function, especially in the meta-
static setting. To discriminate between tumors that are truly
HRD, functional methods such as RAD51 foci staining have been
developed for clinical use to improve selection of patients sensi-
tive to DNA–damaging agents (9,10).
Information on HRDetect scores was available for 24 tumors
in our cohort, of which four were BRCA1 methylated as previ-
ously described ([3]; Supplementary Figure 1, available online).
Table 1. CpG–promoter methylation of BRCA1 gene analyzed with respect to clinicopathological parameters and breast cancer subtypes*
A) ER status with respect to BRCA1 methylation
ER status BRCA1 unmethylated BRCA1 methylated
ER positive 526 (77.5%) 2 (9.5%)
ER negative 153 (22.5%) 19 (90.4%)
Total (N ¼ 700) 679 21
Fisher test, P < .0001
B) Breast cancers subtypes with respect to BRCA1 methylation
Subtype BRCA1 unmethylated BRCA1 methylated
LumA 78 (40%) 0
LumB 61 (31.3%) 1 (8.3%)
HER2 18 (9.2%) 0
Basal-like 34 (17.4%) 8 (66.7%)
5-negative (5NP) 4 (2.1%) 3 (25%)
Total (N ¼ 207) 195 12
v2 ¼ 39.0, P < .0001
C) Histological grade with respect to BRCA1 methylation
Histological grade BRCA1 unmethylated BRCA1 methylated
1þ 104 (23.6%) 0
2þ 187 (42.4%) 6 (31.6%)
3þ 150 (34%) 13 (68.4%)
Total (N ¼ 460) 441 19
v2 ¼ 11.1, P ¼ .0039
D) Tumor size with respect to BRCA1 methylation
Tumor size BRCA1 unmethylated BRCA1 methylated
T1 462 (54.4%) 8 (30.8%)
T2 319 (37.6%) 16 (61.5%)
T3 54 (6.4%) 2 (7.7%)
T4 14 (1.6%) 0
Total (N ¼ 875) 849 26
v2 ¼ 6.9, P ¼ .075
E) Nodal status with respect to BRCA1 methylation
Nodal status BRCA1 unmethylated BRCA1 methylated
Negative 422 (51.9%) 17 (65.4%)
Positive 391 (48.1%) 8 (30.6%)
Total (N ¼ 839) 813 26
Fisher test, P ¼ .15
F) Age at diagnosis
Age BRCA1 unmethylated BRCA1 methylated
55 439 (46.9%) 22 (75.9%)
>55 497 (53.1%) 7 (24.1%)
Total (N ¼ 965) 936 29
Fisher test, P ¼ .002
*ER ¼ estrogen receptor.
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The four BRCA1 methylated tumors all show high HRDetect
scores, comparable to values seen in BRCA1 mutation carriers.
Two of these four received CMF treatment, and both are still
alive today, more than 18 years after their diagnosis.
Recently, in Tutt et al., advanced TNBC tumors where inves-
tigated for response to docetaxel and carboplatin, which
revealed better response to docetaxel. These tumors, however,
were pretreated with drugs that cause DNA lesions that require
DNA DSB repair. As suggested by the authors, BRCA1 methyla-
tion detected in the primary tumor may have been lost follow-
ing this first treatment, thereby explaining the lack of response
to carboplatin in the advanced tumors. Our study differs from
that of Tutt et al. in that we investigate the response to first
treatment in our patient cohort (8).
Of interest, we observe substantially lower frequency of
BRCA1 methylation than previously reported (17,18,44,45). The
discrepancy likely reflects either smaller cohorts in previous
studies, leading to a situation where the detection of a single
methylated tumor greatly influences the frequency, or use of
methods known to have a higher false-positive detection rate,
compared with pyrosequencing, such as methylation-specific
PCR. In our cohort, 3% of primary breast cancer samples are
BRCA1 methylated, which is in agreement with a recent study
using data from The Cancer Genome Atlas (21).
Our cohort is based on DNA samples isolated from freshly
frozen (FF) tumors (n¼ 417) and formalin-fixed paraffin-embed-
ded (FFPE) tumors (n¼ 615). Previous studies have shown higher
fraction of BRCA1 methylation in FFPE samples (46). Our analy-
sis, based on pyrosequencing, does not show statistically signif-
icant differences in frequency of BRCA1 methylation in
noncarriers (n¼ 965) between FFPE (14 out of 587; 2.4%) and FF
(15 out of 378; 4.0%).
A limitation of this study lies in the low number of BRCA1
methylated tumors detected in our cohort. However, we would
like to point out that this is the largest cohort studied to date on
BRCA1 methylation. Another limitation lies in the use of time to
breast cancer–specific death as a proxy for response to treatment.
In summary, we demonstrate that BRCA1 methylation is an
important predictive factor of chemosensitivity in breast cancer
rather than being a prognostic factor. This provides support for
the use of methods aimed at defining BRCAness to identify
patients that will derive benefits from DNA–damaging
Figure 2. Breast cancer–specific survival time in patients treated A) with and B) without cytotoxic chemotherapy analyzed with respect to BRCA1 methylation status.
The P values shown reflect log-rank hypothesis testing for differences in survival times with respect to BRCA1 methylation status.
Table 2. Type of chemotherapeutic drugs used during treatment in
the cohort of non-BRCA mutation carriers listed out with respect to
BRCA1 methylation status*











*CMF ¼ cyclophosphamide, methotrexate, and fluorouracil.
Table 3. The effect of BRCA1 methylation on time to breast cancer–
specific death with and without chemotherapeutic treatment ana-
lyzed by multivariate Cox proportional hazards regression*
Treatment HR (95% CI) P
BRCA1 methylation in
nontreated patients (n ¼ 391)
1.58 (0.52 to 4.80) .416
BRCA1 methylation in treated
patients (n ¼ 183)
0.10 (0.01 to 0.75) .025
*Adjusted for year of diagnosis and birth, estrogen-receptor status, tumor size,
and nodal status. CI ¼ confidence interval; HR ¼ hazard ratio.
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chemotherapy treatment and, possibly, targeted therapy using
PARP inhibitors.
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